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Abstract
Background: Reducing the disease burden of major depressive disorder (MDD) is of major public health relevance.
The prevention of depression is regarded as one possible approach to reach this goal. People with multiple risk factors for
MDD such as chronic back pain and subthreshold depressive symptoms may benefit most from preventive measures.
The Internet as intervention setting allows for scaling up preventive interventions on a public mental health level.
Methods: This study is a multicenter pragmatic randomized controlled trial (RCT) of parallel design aiming to investigate
the (cost-) effectiveness of an Internet- and mobile-based intervention (IMI) for the prevention of depression in chronic
back pain patients (PROD-BP) with subthreshold depressive symptoms. eSano BackCare-DP is a guided, chronic
back pain-specific depression prevention intervention based on cognitive behavioral therapy (CBT) principles
comprising six weekly plus three optional modules and two booster sessions after completion of the intervention. Trained
psychologists provide guidance by sending feedback messages after each module. A total of 406 patients with chronic
back pain and without a depressive disorder at baseline will be recruited following orthopedic rehabilitation care
and allocated to either intervention or treatment-as-usual (TAU). Primary patient-relevant endpoint of the trial is
the time to onset of MDD measured by the telephone-administered Structured Clinical Interview for DSM (SCID)
at baseline and 1-year post-randomization. Key secondary outcomes are health-related quality of life, depression
severity, pain intensity, pain-related disability, ability to work, intervention satisfaction and adherence as well as
side effects of the intervention. Online assessments take place at baseline and 9 weeks as well as 6 and 12 months
post-randomization. Cox regression survival analysis will be conducted to estimate hazard ratio at 12-month follow-up.
Moreover, an economic analysis will be conducted from a societal and public health perspective.
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Discussion: This is the first study examining an IMI for depression prevention in a sample of chronic pain patients. If
this implementation of a depression prevention IMI into orthopedic aftercare proves effective, the intervention could
be integrated into routine care with minimal costs and extended for use with other chronic diseases. Results will have
implications for researchers, health care providers and public health policy makers.
Trial registration: The trial is registered at the WHO International Clinical Trials Registry Platform via the German
Clinical Studies Trial Register (DRKS): DRKS00007960. Registered 12 August 2015.
Keywords: Prevention, RCT, eHealth, Internet and mobile based, Major depression, Chronic back pain, CBT,
Effectiveness, Economic evaluation
Background
Major depressive disorder (MDD) is related to high
disease burden for both people affected and society [1].
In a recent literature review investigating global vari-
ation in the prevalence and incidence of MDD, a global
point prevalence of 4.7%, a lifetime prevalence between
10 and 15% and a global incidence of 3.0% have been
reported [2, 3]. It is estimated that existing psycho-
logical and pharmacological treatments have the poten-
tial to avert only 36% of the burden of MDD, and only
when assuming perfectly efficient provision of existing
treatments in terms of coverage, patient compliance, an
d clinician competence [4, 5]. Thus, we are either in
need of more powerful interventions for treating de-
pression or we should aim at diminishing the likelihood
of developing depression in the first place, highlighting
prevention of depression as a promising approach. Re-
cent research suggests that psychological preventive
interventions such as cognitive behavioral therapy (CBT) or
interpersonal psychotherapy have the potential to prevent a
clinically significant number of new depression cases [6]. A
meta-analysis of 32 randomized controlled trials (RCTs) re-
ported a reduced incidence rate for MDD of 21% (incidence
rate ratio = 0.79, 95% confidence interval: 0.69–0.91) when
comparing psychotherapy-based preventive interventions
with usual care or wait list conditions.
While the effectiveness of preventive interventions
seems sufficiently documented, it remains challenging to
identify target populations that benefit most from pre-
ventive measures [7]. According to Cuijpers and col-
leagues [8] two factors need be taken into account: the
“impact” and the “effort” of preventive measures. An ad-
equate “impact” means that prevention must lead to a
substantial reduction of total disease burden. Therefore,
a substantial proportion of new cases must be prevented
if assembled risk indicators are fully blocked. A reason-
able level of “effort” is primarily defined as a low number
needed to be treated (NNT) to prevent one new case of
MDD. Additionally, persons at risk should be easily
identifiable and interventions should not only be cost-
effective but also low priced to allow for their implemen-
tation at a population level.
From this viewpoint, chronically medically ill patients
appear to be a meaningful target population for the
prevention of MDD, given the substantially increased
prevalence for MDD in this population compared to
the general population [9, 10]. In addition, comorbid
MDD in medically ill patients is associated with nu-
merous negative implications such as problems in the
physician-patient relationship, increased risky health-
related behaviors, higher medical symptom burden,
medical complications, lowered quality of life and in-
creased mortality [11, 12]. Within the group of medic-
ally ill persons, back pain is one of the most common
conditions [10, 13] and is associated with a two to
three-fold increased risk for MDD [14]. In addition,
depression is one of the core predictors of persistent
pain symptoms, increased pain related disability, and
poor treatment outcomes, and is associated with in-
creased morbidity and health care costs as well as di-
minished quality of life [11, 12, 15–17].
The benefits of prevention can be multiplied by focusing
on patients who already show some depressive symptoms
due to several reasons. First, subthreshold depressive
symptoms are an additional risk indicator for MDD
[18, 19]. Multiple risk groups have increased specificity
for prevention measures which leads to a reduction of
NNT (“effort”) [20] and leading to greater cost-
effectiveness of preventive interventions. Second, by
lowering the NNT, the number of persons who are not
in need of a preventive intervention, but receive it, will
be reduced. Third, subthreshold depression itself is a
considerable disease burden for people affected and for
society [21, 22]. A successful preventive intervention will
not only reduce the risk of developing MDD but also im-
prove depression symptom severity at all levels of depres-
sion, as shown by a recent meta-analysis (pooled effect
size g = 0.35, 95%-CI: 0.23–0.47; [23]). Fourth, uptake rates
of a depression prevention intervention may be higher in
a target population of patients with depressive symptoms,
as treatment utilization was found to be associated with
severity of baseline depression [24].
The internet is an appropriate prevention medium for
scaling up preventive interventions as units of delivery
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are reasonably priced and can be easily administered
[7, 25]. It has several additional advantages as dis-
cussed elsewhere [26–28].
In prior studies, Internet- and mobile-based interven-
tions (IMI) have shown to be effective in the treatment of
MDD [29, 30] as well as in the treatment of subthreshold
depression, indicating their potential to be utilized for pre-
ventive interventions [25, 31–34]. Human support (guid-
ance) has repeatedly been shown to have a positive effect
on effectiveness of and adherence to IMIs [35, 36].
The proposed study aims to investigate the effectiveness
and cost-effectiveness of an IMI (eSano BackCare-DP) to
prevent the onset of depression for chronic back pain
patients (PROD-BP) with subthreshold depressive symp-
toms. The study will be embedded into routine orthopedic
care in order to examine the intervention’s effectiveness in
an unselected sample of all eligible chronic back pain
patients (i.e. the implementation will not be limited to
a self-selected population of people who are already
attracted to depression prevention interventions and
the Internet). It is expected that
1) eSano BackCare-DP is effective in preventing the
onset of MDD compared to treatment as usual
(TAU) over a 12-month follow-up period,
2) eSano BackCare-DP is cost-effective compared to TAU.
3) Compared to TAU, eSano BackCare-DP is superior
in terms of (a) depression response, (b) work capacity,
(c) quality of life, (d) pain related disability and (e)
pain intensity.
Furthermore, the distributions of principal confounders
in each group will be explored.
Methods
Study design
This project is a multicenter randomized controlled clinical
trial (RCT) of parallel design comparing the effectiveness
and cost-effectiveness of a guided depression prevention
IMI with treatment as usual (TAU) (Fig. 1). All participants
will receive TAU. Participants of the intervention group will
additionally receive the IMI eSano BackCare-DP.
This clinical trial will be conducted and reported in
accordance with the CONSORT-supplement for prag-
matic RCTs [37] and the guidelines for executing and
reporting internet-based intervention research [38]. In
order to guarantee data quality and safety, the Clinical
Trials Unit Freiburg will perform monitoring visits to
the recruitment centres before, during and after com-
pletion of the study. Moreover, an independent Data
Safety and Monitoring Board (DSMB) has been estab-
lished. It consists of two experienced scientists and psy-
chotherapists (MHä, MHa) and a statistician (LK) with
long-standing experience in clinical trials.
Inclusion and exclusion criteria
Patients who provide written consent will be included in
the study if they meet the following criteria: a) age 18
and above, b) presence of chronic back pain assessed by
physician diagnosis and participants report on pain
chronicity (>6 months), c) sufficient knowledge of Ger-
man language, d) internet access, e) persistent sub-
threshold depressive symptomatology (Patient Health
Questionnaire (PHQ-9) ≥ 5 in two consecutive screenings
within 2–3 weeks. If only one PHQ is over cut-off, a third
PHQ will be administered 2 months later.
Patients will be excluded who meet DSM criteria for a)
current depressive episode or depressive episode within the
last 6 months (following Kupfer [39]), b) current dys-
thymia, c) current or lifetime bipolar disorder. Additionally
patients will be excluded in case of d) participation in on-
going psychotherapy, completed psychotherapy in the past
6 months, or being on a waiting list for psychotherapy (be-
ginning within 3 months), e) currently suicidal or reporting
suicidal attempts within the past 5 years. Patients with a
diagnosis of any affective disorder will receive information
on possible mental health care options, including the offer
to take part in a parallel clinical trial for the treatment of
depression in patients with chronic back pain and clinical
depression [40]. In cases of severe depression, a trained
psychotherapist from the study team [HB, SaS, LS] will
contact the participant to initiate further actions.
Setting/Recruitment
Recruitment has started in October 2015. Recruitment
will continue until the target sample size has been reached.
Participants are recruited in the aftermaths of their ortho-
pedic rehabilitation care. In order to increase the represen-
tativeness of our sample, we established two comparable
recruitment strategies. First, back pain patients from eight
orthopedic rehabilitation units are screened at admission
and discharge. Clinical staff informs and recommends par-
ticipation to patients screened positive (personal re-
cruitment). In addition, an information flyer and a
patient information form with a detailed description of
the study process and information on the intervention
are provided. Patients providing their informed consent
are contacted by the study team in order to clarify fur-
ther eligibility criteria by means of an online- and tele-
phone assessment including a telephone administered
clinical interview (SCID; [41–43]).
Second, back pain patients from orthopedic rehabilitation
units across Germany receive a letter with the same infor-
mation flyer and study process information (recruitment by
letter). Interested back pain patients fill out an online
PHQ-9 screening. Positive screened patients (PHQ-9 ≥ 5)
providing their informed consent conduct the aforemen-
tioned online- and telephone assessment including a
second PHQ-9 screening to ascertain persistent
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depression in line with the first recruitment strategy
(second PHQ-9 ≥ 5). A third PHQ-9 screening takes
place 2 months afterwards in case of only one PHQ-9
being screening positive. Eligible back pain patients
from both recruitment strategies receive an email pro-
viding further information and a link referring to the
intervention website. All participants are free to seek
any additional help during the trial. Trial participants
receive 15€ for the completed follow-up telephone
assessment.
Randomization
Participants eligible for inclusion will be randomly
allocated to one of two groups (intervention or TAU).
Randomization and allocation will be prepared in
advance by a researcher (SaS) who is responsible for
administration of the trial and participants. This re-
searcher will remain blinded to all processes within the
intervention. An automated, web-based randomization
program (www.sealedenvelope.com) will be used, which
features permuted block randomization, variable block




The intervention (eSano BackCare-DP) consists of six
weekly sessions plus three optional modules and two
booster sessions of approximately 45 to 60 min each (see
Figs. 2 & 3). Participants can decide when to complete
the booster sessions at the end of the last session. They
can choose two dates within a timeframe of 3 months
following the intervention, and will be reminded to log-in
again. Sessions can be repeated as often as desired. All
modules consist of information about depression and
(chronic) back pain, provided by text, audio, and video, as
well as assignments, metaphors and exercises. The con-
tent of the intervention is based on cognitive behavioral
Personal recruitment in eight orthopedic facilities: 
all chronic back pain patients
Recruitment by letter after discharge from 
orthopedic facilities: all chronic back pain patients
2 consecutive depression screenings within 2-3 weeks (PHQ-9)
(if one PHQ-9 < 5, additional PHQ-9 two months later)
Not meeting criteria:
• Declined to participate (no informed 
consent)
• Less than 2 PHQ-
• Suicidal risk
• No adequate computer and internet 
access/skills
Online and telephone assessment (T0) 
Not meeting criteria:
• Acute affective disorder (SCID)
• History of MDD in the past 6 months
• Psychotherapy (on a waiting list for, 
currently or in the past 6 month)







Online and/or telephone assessment 9 weeks (T1), 6 months (T2) and 12 months (T3) after randomization
Allocation
Follow-Up
Fig. 1 Flow chart of inclusion and study procedure
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therapy (CBT) for depression, including elements of
psychoeducation, social skills, problem solving, behavioral
activation, improving self-care, relaxation and motivation
for physical exercises. The intervention is based on prior
interventions that have been evaluated in a number of
RCTs in different samples [31, 34, 44–46]. We adapted
and substantially extended the predecessors to the context
of depression prevention and chronic back pain. In order
to address chronic back pain patients specifically, psycho-
logical pain intervention elements are integrated in every
module of the intervention. Moreover, three optional
modules are offered, focusing on problems with sleep,
partnership/sexuality and returning to the workplace.
Emphasis is laid on homework assignments, which are
intended to provide practice of learned skills. To enhance
patient adherence, interactive elements (quizzes, condi-
tional contents) are implemented. Participants will be asked
about adverse events at the beginning of every session with
the advice to check whether it is the right time to go on
with the session. The intervention platform is provided by
Minddistrict (www.minddistrict.com), a company spe-
cialized in the provision of web-based health interven-
tions. Access to the platform proceeds through a unique
username-password combination and will be available
on a 24/7 basis. All transferred data will be secured
based on ISO27001 and guidelines NEN7510.
Text message coach
At the beginning of the training, participants are asked
if they want to receive daily reinforcing text messages
during the 6-week training period. Text message
prompts have been shown to be beneficial in internet
interventions with positive effects on efficacy and
adherence [47–49]. The messages are sent automatic-
ally and coordinated with intervention content in
order to integrate the learned techniques into daily life
of the participants. Message content aims at remind-
ing patients to complete homework assignments, re-
peating training content, and reinforcing motivation of
participants.
Guidance
Trained and supervised (by HB, JL, SP) psychologists
(eCoaches) will guide participants during the training
by providing a semi-standardized feedback within 2
working days after each completed session, using an
eCoach manual. The eCoach manual is standardized
to ensure protocol adherence by the eCoaches. All
communication between eCoaches and participants
runs via the intervention platform. Guidance time
spent per participant per intervention will be mea-
sured to provide data for the economic analyses of the
project. The feedback content will match the partici-
pants’ assignments and provide support for treatment
adherence. Feedback also includes positive reinforcement
to encourage participants to continue with the train-
ing. If any further questions arise, participants and
eCoaches can contact each other at any time via the
intervention platform. eCoaches will also send re-
minders to participants, who do not complete inter-
vention modules on time.
Control condition
Participants of the control condition will have unre-
stricted access to TAU. Although national treatment
guidelines for low back pain and depression exist [50],
TAU following orthopedic rehabilitation care may
vary. There is no minimum treatment defined and
TAU will not follow a standardized protocol; however,
all received types of medical/psychological help during
the last 3 months will be monitored with the Trimbos/
Fig. 2 Intervention structure, technical implementations and support
Fig. 3 Intervention content, based on Cognitive Behavioral Therapy
(CBT), including back pain specific self-management
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iMTA questionnaire, to account for all costs associated
with psychiatric illness (TIC-P) [51]. Using these data, an
accurate description of TAU can be provided.
Sample size/power calculation
The aim of the study is to compare the effectiveness of
the intervention against TAU using a cox regression
survival analysis with a significance level of 5%. Based
on previous studies of depression incidence in chronic
back pain patients and subclinical depression, we expect a
mean incidence of MDD of 20% in the control group
within the 12-months follow-up period [52–55]. Based on
a prior conducted trial, we assume an absolute risk reduc-
tion of 9% with a respective hazard ratio of 0.522 between
treatment and control group at 12 months after
randomization [34]. A total of 64 events (event = onset
of depression) need to be observed to detect a 47.8%
decrease in hazard (hratio = 0.522) of the treatment
group relative to the hazard of the control group
based on a power of 80%. Accordingly, 406 partici-
pants (203 per group) need to be randomized (calcu-
lated using Stata/SE 13.1). The inclusion of relevant
baseline predictors of depression onset will further in-
crease power (e.g. baseline depression severity). Re-
cruitment will be continued to allow for an expected
attrition rate of 20%.
Assessments
Assessments will be conducted at pre-treatment (T0)
and at 9 weeks, 6- and 12-months follow-up (T1, T2,
T3; see Table 1). All self-report assessments, potentially
effect-modifying covariates and demographic variables
will be provided using a web-based interface integrated
into the intervention platform. Section A (Affective
Syndromes) of the SCID [43], the Hamilton Rating
Scale for Depression (HAM-D-17 [56]) and the Quick
Inventory of Depressive Symptomatology (QIDS-C16;
[57]) will be performed via telephone interviews at T0
and T3. Moreover, we translated the SCID-V-RV into
German to be able to comment on DSM-IV and -V [58]
diagnoses.
Videos promoting the importance of collecting data
will be implemented into online assessments to enhance
compliance with completing measures. In psychological
intervention trials, blinding of study participants and
eCoaches is not possible. However, all members of the
research team conducting telephone administered out-
comes will remain blinded. Therefore, both participants
and interviewers will be reminded of the reason and im-
portance of blinding at the beginning of each interview.
Moreover, performance bias will be minimized, as the
web-based intervention is separated from other health
care services.
Procedure on suicidal ideation
The telephone interviews (SCID, HAM-D, QIDS) and
questionnaires (PHQ-9) include a suicide screening to
identify participants who are currently suffering from
suicidal ideation. We will follow a suicide protocol
adapted from prior trials [31, 44] if participants score on
any suicidality item. Participants who report low suicidal
ideation (HAM-D, QIDS or PHQ-9 item score = 1) will
receive an email with detailed information on available
health services and the advice to seek professional help
if symptoms increase. If participants express moderate
to high suicidal ideation during the assessment or
express any suicidal thoughts or intentions to their
eCoach, a trained psychotherapist from the study team
[EM, LS, HB, SaS] will contact the participant and initiate
further actions.
Outcome measurements
Primary outcome: Time to onset of MDD
To assess the time to onset of MDD within the 12-month
follow-up period, the depression related modules of SCID
will be part of the telephone assessment [41, 59]. The
SCID is a comprehensive, structured interview designed
to be used by trained interviewers for the determination
of mental disorder diagnoses according to the definitions
and criteria of DSM. It enables a reliable, valid and effi-
cient assessment of depressive disorders [59]. Inter-rater
reliability of the SCID was reported to be moderate to
high and high for inter-rater reliability comparing tele-
phone and face-to-face interviews [60, 61].
Interviewers are trained and weekly supervised by
clinical psychologists (LS, EM) and are blinded to
randomization condition. After the training period,
supervisors and the interviewers assess participants
together, with comparison of results as follows: The
Inter-Rater Reliability (IRR) for the SCID, measured
by Cohen’s kappa and the Intra-Class Correlation for
the HAM-D and QIDS. An almost perfect Cohen’s
kappa ≥ .81 [62] and an excellent ICC coefficient ≥ .75
[63] are considered as sufficient. Moreover, the
interviewers are compared to each other on a random
basis to assess the IRR.
Time to onset of MDD will be assessed using life
charts. Therefore, life events will be recalled using a cal-
endar method to determine presence of symptoms at
each month within the follow-up period. Supervisors are
blinded to participants’ group allocation.
Secondary outcomes
Depressive symptoms
Depressive symptoms will be assessed by the self-
administered Patient Health Questionnaire (PHQ-9)
[64], a telephone-based clinician rating of the Hamilton
Rating Scale for Depression (HAM-D-17), and the
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Quick Inventory of Depressive Symptomatology (QIDS)
[56, 57]. The PHQ-9 is a well validated and widely used
depression screening instrument [64] and has also been
evaluated to be delivered as online-version [65]. The 17-
item HAM-D is the most widely used clinician-rated
measure of depression severity and as such viewed as the
gold standard for the assessment of depression severity.
The 16-Item QIDS will be used to further validate the de-
pressive symptom outcome measures. It covers all criter-
ion symptom domains of the DSM for diagnosing a MDD
[57]. HAM-D and QIDS are administered to determine
depression response [66].
Quality of life
To assess health-related quality of life, the Assessment of
Quality of Life (AQoL-6D) will be used, which includes 20
items assessing the following dimensions: independent liv-
ing, mental health, coping, relationships, pain, and senses
[67]. Besides measuring health-related quality of life, the
AQoL-6D is suitable for economic evaluations of health
programs and has good psychometric properties [67]. It has
also shown to be reliable, with a Cronbach’s alpha of .89
[68]. Because this is a relatively new instrument, we add-
itionally will use the EuroQol (EQ-5D-5 L), the most widely
used quality of life assessment, as a basis for cost-utility
Table 1 Outcome assessments and assessment time point
Variables Measurement Screening T0 T1 T2 T3
Inclusion/exclusion criteria
Chronic Back pain MR + TI x x
Depressive symptomatology PHQ-9 x x x x x
Inclusion criteria a), c), d) TI/SRQ x
Acute/past 6 months depressive episode, dysthymia or
bipolar disorder
SCID x x
Current/past 6 months/on waiting list for psychotherapy TI x
Suicidality SCID/HAM-D/QIDS x x
PHQ-9 x x x x x
Primary outcome
Onset of Depression SCID x x
Secondary outcomes
Severity of depressive symptoms PHQ-9 x x x x x
HAM-D/QIDS x x
Quality of life AQOL-6D/EQ-5D-5 L x x x x
Pain intensity Rating scale x x x x
Pain related disability ODI x x x x
Pain self-efficacy PSEQ x x x x
Ability to work SPE x x x x
Economic evaluation
Costs TiC-P x x x
Quality of life AQOL-6D/EQ-5D-5 L x x x x
Covariates
Demographic variables SRQ/MR x x
Depression type and chronicity SCID x x
Patient adherence Attrition rate x x
Patient satisfaction CSQ-8a x
Side-effects of intervention INEPa x x
Back Pain type and chronicity MR x
Internet affinity IAS x
AQol-6D Assessment of Quality of Life, CSQ-8 Client Satisfaction Questionnaire, EQ-5D-5 L European Quality of Life scale, HAM-D Hamilton Rating Scale for
Depression, IAS Internet Affinity Scale, INEP Inventory for the Assessment of Negative Effects of Psychotherapy, MR Medical record, ODI Oswestry Disability Index,
PHQ-9 Patient Health Questionnaire, PSEQ Pain Self-Efficacy Questionnaire, SCID Structured Clinical Interview for DSM, SPE Subjective Prognostic Employment scale,
SRQ Self-report assessment questionnaire, TI telephone interview, TiC-P Trimbos/iMTA questionnaire for costs associated with psychiatric illness
aintervention group only
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analyses [69]. The EQ-5D measures five health domains of
importance to quality of life: mobility, self-care, usual activ-
ities, pain/discomfort, and anxiety/depression. The 5-level
version includes five levels of response, which has been
found to be more discriminative and to reduce ceiling ef-
fects compared to the 3-level version [70, 71].
Pain intensity and pain associated disability
Pain intensity and pain-related disability will be measured
following the IMMPACT recommendations for core out-
come measures for chronic pain clinical trials [72, 73]. Pain
intensity will be measured by an 11-point numerical rating
scale (0-10) of pain intensity as well as categorical classifi-
cation of pain intensity (none, mild, moderate, severe). The
Oswestry Disability Index (ODI) will be used to assess pain
related disability. The ODI is a reliable and valid self-
assessment questionnaire including 10 items [74].
Pain self-efficacy
Self-efficacy with regard to pain management will be
assessed by using the Pain Self-Efficacy Questionnaire
(PSEQ), which is a validated and reliable (internal
consistency: α = 0.93) 10 item instrument that assesses
self-efficacy expectations related to pain [75].
Work capacity
Work capacity will be assessed using the German version
of the Subjective Prognostic Employment Scale (SPE), a
validated 3-item self-report questionnaire with high in-
ternal consistency (Guttman scaling: rep = .99) [76].
Intervention satisfaction and adherence
Patient satisfaction with the intervention will be mea-
sured by using an adaptation of the Client Satisfaction
Questionnaire (CSQ-8, German: ZUF-8), optimized for
the assessment of client satisfaction with online inter-
ventions (CSWIQ-8) [77]. The CSQ-8 is a validated 8
item instrument with high internal consistency (α = 0.93)
[78]. The adapted version, validated for the assessment
of client satisfaction in web-based interventions, has
been shown to have high internal consistency in a range
of studies (α = 0.92-0.94) and is associated with treat-
ment adherence and outcome [79–81]. The attrition rate
(i.e. percentage of participants who no longer use the
intervention assessed by their log in data) will give an
estimate of the participants’ intervention adherence.
Side effects of psychotherapy
The German version of the Side Effects of Psychotherapy
Inventory (INEP) [82] will be used to measure side-effects
of psychotherapy. The INEP consists of 15 items assessing
a range of common changes participants may have experi-
enced due to the effects of the preventive intervention in
their social and work environments.
Costs
To measure costs, the Dutch cost questionnaire: “Trimbos
Institute and Institute of Medical Technology Question-
naire for Costs Associated with Psychiatric Illness” (TiC-P)
[51], adapted for the German health care system, will be
used [83]. The TiC-P is a widely used self-report question-
naire to measure health care consumption and productivity
loss [84]. We further adapted the questionnaire for the
population of chronic back pain patients. Participants will
register all direct health service uptakes during the last
3 months, e.g. the number of general practice visits,
sessions with psychiatrists, and hospital days. In addition,
productivity-related costs will also be assessed. This in-
cludes the number of ‘work loss’ days (absenteeism), the
number of ‘work cut-back’ days (presenteeism), and costs
associated with for domestic tasks. Estimated development
costs as well as opportunity costs will be included in the
economic evaluation.
Covariates
As potentially effect-modifying covariates, demographic
variables (gender, age, education), social support and
medical variables (prior pain and depression treatments)
will be assessed via self-report at baseline. Internet com-
petencies will be assessed by the Internet Affinity Scale
[85]. The translated version by Haase and colleagues
[86] will be used. Back pain type, severity and chronicity
will be extracted from medical records.
Statistical analysis
Clinical analyses
All analyzes will be performed according to the intention-
to-treat (ITT) principle. Kaplan-Meier curves and Cox
proportional hazard regression analysis will be used to
determine differences in time to onset of MDD in weeks
between both study conditions over a follow-up period of
12 months. The dependent variable will be time to onset
of MDD and treatment condition will be the independent
variable. The proportional-hazards assumption will be
tested based on the scaled Schoenfeld residuals test.
Survival analysis assumes that censoring (i.e., a participant
is lost-to-follow-up or completes the follow-up period
without experiencing a major depressive episode) is non-
informative. Non-informative implies that the reasons
why participants drop out of the trial are unrelated to the
study condition (i.e., participants in one study arm should
not be routinely censored). We will apply the following
methods to deal with informative censoring, if necessary:
(a) imputation techniques for missing data, (b) sensitivity
analyses to illustrate best and worst case scenarios to test
the robustness of the base case findings and (c) the use of
the drop-out event as a study end point [87]. In addition,
the number needed-to-treat (NNT) to prevent one add-
itional event in the intervention group versus the control
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group will be calculated [88]. Covariates will first be
checked whether they are associated with the primary
outcome, if not left out of the final analysis.
Secondary outcomes will be analyzed using hierarchical
linear modeling. To examine potentially moderating co-
variates, correlation of covariates and outcome parameter
are analyzed using multiple regression models. In addition,
per protocol analysis will be performed to investigate the
influence of drop-outs on study results. Missing data will
be imputed using multiple imputation. Potential con-
founding factors between source population and study
population will be assessed, which enables us to evaluate
the external validity of the sample. Finally, characteristics of
dropped out participants at follow-up will be inspected and
resulting socio-demographic differences between interven-
tion and control group will be described. A significance
level of p ≤ .05 will be set for all analyses.
Economic evaluation
Baseline utilities and costs will be compared between
both groups and if necessary, statistical techniques will
be used to adjust for baseline differences [89]. In the
cost-effectiveness analysis, the incremental cost-effectiveness
ratio (ICER) will be presented as costs per depression-free
year (DFY) gained. DFYs will be based on the number of de-
pression-free weeks up to onset of a major depressive
episode within the 12-month follow-up period. The
ICER in the cost-utility analysis will be stated as costs per
quality-adjusted life year (QALY) gained. Non-parametric
bootstrapping (2500 times) will be applied to estimate the
robustness of the ICERs and to quantify the uncertainty
around the ratios. The bootstrapped replicates of the
ICERs will be graphically represented in a cost-
effectiveness plane, with effects along the horizontal
axis and costs along the vertical axis.
In addition, a cost-effectiveness acceptability curve will
be graphed to assess the probability that the intervention
is more cost-effective relative to treatment as usual at
varying willingness-to-pay (WTP) ceilings.
Discussion
This study will be the first to investigate the effectiveness
and cost-effectiveness of a psychological Internet- and
mobile-based intervention for the prevention of depres-
sion in a chronic pain population. Due to its recruitment
strategy from routine medical health care, the entire po-
tential target group can be reached within a naturalistic
setting. Results will have implications for researchers,
health care providers and public health policy makers.
Conducting IMI-trials commonly involves possible
limitations, which we try to overcome using the following
measures. First, web-based interventions can have moder-
ate to high drop-out rates [90–93], and drop-out rates can
be expected to be even higher in preventive interventions
due to the lower symptom burden of participants. We will
approach this problem in different ways: a) by focusing on
patients with current depressive symptoms b) by providing
guidance via eCoaches, which has been shown to have an
adherence-facilitating effect [35, 36], and c) by explicitly
facilitating at risk participants’ motivation to use the inter-
vention after discharge from orthopedic rehabilitation
care. In a prior IMI with diabetes patients, participants
completed an average of 78.3% of all sessions [44]. In a
sample of subthreshold depressed patients, participants
completed an average of 82.2% [31]. These results corres-
pond to findings from a recent meta-analysis on adher-
ence to internet-based CBT (ICBT) [94]. Van Ballegooijen
and colleagues concluded that adherence to guided ICBT
could be equal to adherence to face-to-face CBT. Partici-
pants do not necessarily have to complete all sessions to
benefit from IMIs. They may also stop the treatment be-
cause they have recovered [95] or experienced improve-
ment in symptoms, thereby reducing the likelihood of
developing depression. These cases would represent a pre-
vention success rather than a treatment drop-out [90].
A second limitation of most Internet- and mobile-
based trials to date (including those mentioned above)
are their highly selective online recruitment strategies.
This may explain the promising results concerning
drop-out rates, as participants already connected to the
Internet comprised the intervention groups. As a down-
side, however, those recruitment strategies lead to a lack
of external validity [27, 96, 97]. In our study, we address
this problem through the integration of the intervention
into routine care. Thereby, the entire potential target
group will be offered the opportunity to take part in the
preventive intervention. The two different recruitment
strategies will allow for analyses on different dissemin-
ation and implementation strategies of IMIs into routine
healthcare. Thus, we can estimate what kind of patients,
and to which extent, make use of the offer to take part
in a preventive IMI within the whole group of chronic
back pain patients.
Third, IMIs can have negative side effects [98–100].
For this reason, we followed the key recommendations
of Rozental and colleagues [98]. We increased the flexi-
bility of the treatment schedule by giving participants
the possibility of delay at the beginning of each session,
and increased flexibility of therapist contact for patients.
Additionally, we prolonged treatment duration by adding
two booster sessions after the main treatment modules.
Furthermore, negative side effects of treatment will be
assessed on a regular basis and reasons for drop-out
from intervention will be assessed.
The specific strengths of this study are the following:
a) Prevention studies are regularly methodologically lim-
ited because they lack a diagnosis at baseline and/or
follow-up [6]. By carrying out the SCID prior to study
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start and at 12-months follow-up a high content validity
can be ensured. b) With a target sample of 406 partici-
pants, the study will be optimally powered, overcoming
the small scale trial limitations of most prior prevention
studies [6, 20]. Following the ITT principle contributes
to reducing overestimation of clinical effectiveness. c)
The intervention is specifically tailored to the special
needs of the target group of chronic back pain patients.
This has been discussed as having an uptake and adher-
ence facilitating effect [27]. We aim to further facilitate
adherence through the integration of the intervention
into patients’ routine healthcare, which enables clinicians
to inform participants about the characteristics and
effectiveness of IMIs. This may have a positive impact
on their acceptance [101]. d) Using the internet as the
medium for prevention might allow for scaling up of
preventive interventions on a public mental health level.
e) The direct implementation of the intervention into
the health-care system increases external validity in con-
trast to prior RCTs [31, 102].
High prevalence rates underscore that the integration
of depression prevention into curative care systems for
the medically ill is one of the major emerging global
health challenges. If this study - the first of its kind –
shows to be effective, the intervention could be imple-
mented into general (chronic) back pain and mental
health treatment protocols as well as adapted to other
chronically ill patient groups, thus helping to reduce the
disease burden of depression for both affected persons
and society. Thus, the results of this study will be of
major public health relevance.
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